—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Apogee Therapeutics, Inc. Common Stock (APGE) — Quality & forensics

As of 2026-10-29 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.

The Closelooknet module scores

40 /100 composite · 6 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

183.54 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

2/7 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

Continue: the APGE chart & overview · the earnings record

FAQ · from the current data · as of 2026-10-29

Quick answers

What is Apogee Therapeutics, Inc. Common Stock's Closelooknet quality reading?

The composite reads 40/100 across 6 modules, as of 2026-10-29: quality 4, growth 26, balance sheet 98, cash quality 21, capital allocation 10, momentum 98. Closelooknet scores are research diary readings, not ratings or investment advice.

What is Apogee Therapeutics, Inc. Common Stock's Altman Z-Score?

183.54, which sits in the safe zone (above 2.99) as of 2026-10-29. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Apogee Therapeutics, Inc. Common Stock's Piotroski F-Score?

2 of 7, as of 2026-10-29. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.